Table 3.
Tepotinib-related TEAEs
| TEAE, n (%) | Tepotinib 215 mg once daily (n = 3) | Tepotinib 300 mg once daily (n = 3) | Tepotinib 500 mg once daily (n = 6) | Total (n = 12) |
|---|---|---|---|---|
| Any grade | ||||
| Amylase increase | 0 | 0 | 2 | 2 (16.7) |
| Lipase increase | 0 | 0 | 2 | 2 (16.7) |
| Serum creatinine increase | 0 | 0 | 1 | 1 (8.3) |
| Hypoalbuminemia | 0 | 0 | 2 | 2 (16.7) |
| Decreased appetite | 1 | 0 | 0 | 1 (8.3) |
| Hyponatremia | 0 | 0 | 1 | 1 (8.3) |
| Nausea | 0 | 0 | 1 | 1 (8.3) |
| Stomatitis | 0 | 0 | 1 | 1 (8.3) |
| Vomiting | 0 | 0 | 1 | 1 (8.3) |
| Fatigue | 1 | 1 | 0 | 2 (16.7) |
| Dysgeusia | 1 | 0 | 1 | 2 (16.7) |
| Acneiform dermatitis | 0 | 0 | 1 | 1 (8.3) |
| Grade 3/4 | ||||
| Lipase increase (grade 4) | 0 | 0 | 2 | 2 (16.7) |
| Hyponatremia (grade 3) | 0 | 0 | 1 | 1 (8.3) |